Caspase-3-mediated Cleavage of the NF-kappa B Subunit p65 at the NH2 Terminus Potentiates Naphthoquinone Analog-induced Apoptosis*

Kyung-Hwa KangDagger , Kyung-Hye LeeDagger , Mie-Young Kim§, and Kyung-Hee ChoiDagger

From the Dagger  Department of Biology, College of Natural Sciences, and the § Division of Biochemistry, College of Pharmacy, Chung-Ang University, Seoul 156-756, Korea

Received for publication, February 8, 2001, and in revised form, April 2, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The transcription factor nuclear factor kappa B (NF-kappa B) plays a crucial role in immune and inflammatory response, and protects cells from apoptosis. In this report, we investigate whether the NF-kappa B signaling pathway is blocked during apoptosis induced by 2,3-dichloro-5,8-dihydroxy-1,4-naphthoquinone (NA), an analog of naphthoquinone. It is observed that NA triggers apoptotic cell death in HeLa cells and destroys resistance to apoptosis caused by tumor necrosis factor-alpha . Data presented in this study establish that p65/RelA, a subunit of NF-kappa B, is cleaved at Asp97 by caspase-3 during apoptosis. Caspase-3-cleaved p65 loses transcriptional activity and potentiates NA-induced apoptosis, in contrast to an uncleavable mutant of p65, which protects the cell from apoptosis. Caspase-3, which is responsible for the cleavage of p65, is activated via the cytochrome c/caspase-9 signaling pathway rather than Fas/caspase-8 pathway during NA-induced apoptosis. Our results suggest that NA induces apoptosis by the negative regulation of cell survival through caspase-3-mediated cleavage of p65.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Apoptosis is initiated by a wide variety of stimuli, including developmental signals, cellular stress, and disruption of the cell cycle. Although the cellular mechanisms underlying apoptosis vary according to the type of stimuli involved, it is generally believed that apoptosis can be induced by the activation of pro-apoptotic signaling or inhibition of survival signaling. A well known survival signal pathway is mediated by the transcription factor, nuclear factor kappa B (NF-kappa B)1 (1-3).

NF-kappa B exists as a dimeric complex, comprising different members of the Rel family: p50, p52, p65, c-Rel, and RelB; all of which contain a well conserved amino-terminal 300 amino acid region. This part of the sequence, known as the "Rel homology region," is responsible for DNA binding, dimerization, and nuclear localization (1, 2). In unstimulated cells, NF-kappa B is located in the cytoplasm as an inactive complex through interactions with inhibitory proteins, Ikappa Balpha and Ikappa Bbeta . Upon cellular stimulation processes, such as cytokine induction or ionizing radiation, Ikappa Bs are rapidly phosphorylated and degraded. This in turn releases NF-kappa B, allowing translocation into the nucleus, binding to specific kappa B sites, and subsequently inducing the expression of target genes responsible for cell survival (4-8).

Previous studies have shown that activation of NF-kappa B is inhibited by a variety of mechanisms. The prevention of degradation or induction of Ikappa B synthesis leads to the inhibition of NF-kappa B activation (9-11). Inhibition of p65 phosphorylation, which is important for the activation of p65, has also been known to suppress transcriptional activity of NF-kappa B (12). Moreover, the cleavage of NF-kappa B by caspases inhibits its activity during apoptosis (13, 14). These reports indicate that inactivation of NF-kappa B activity plays a crucial role in the apoptotic pathway.

Vitamin K3 (menadione) induces growth arrest and apoptosis in various cancer cell lines (15). Despite a broad-range effect on growth suppression of cancer cells, its hydrophobicity presents difficulties for use as an anticancer drug. Earlier experiments focusing on a search for new naphthoquinone analogs with polar groups led to the discovery of 2,3-dichloro-5,8-dihydroxy-1,4-naphthoquinone (NA) by our group (16). NA induced growth inhibition more potently than other analogs and natural VK3, without producing ROS in human hepatocarcinoma cells (15, 16). In view of the fact that, as yet, little is known about the mechanism of action of NA, this study involves a detailed investigation into the molecular function of NA in apoptosis.

In this report, we demonstrate that NA inhibits tumor necrosis factor alpha  (TNF-alpha ) induced activation of NF-kappa B and induces apoptosis of HeLa cells. NA potently inhibits transcriptional activity of NF-kappa B through caspase-3-mediated proteolytic cleavage of p65 at Asp97. Truncated p65 leads to the inhibition of transcriptional activity of NF-kappa B, and therefore the promotion of NA-induced apoptosis, while in contrast, uncleavable mutant p65 protein protects cells from apoptosis. These observations suggest that the activation of NF-kappa B is inhibited by caspase-3-mediated cleavage of p65, indicating that the survival pathway mediated by NF-kappa B might be abolished during NA-induced apoptosis.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture and Reagents-- Human cervical epitheloid carcinoma (HeLa) cells were cultured in Dulbecco's modified Eagle's medium (Life Technologies, Inc.) supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies, Inc.) at 37 °C, in a humidified incubator with an atmosphere of 5% CO2. Unless specified otherwise, all reagents were purchased from Sigma.

Cell Proliferation and Apoptosis Assays-- HeLa cells were seeded in 35-mm plates at an initial density of 2 × 104 cells/plate. Cells were cultured for 16-20 h in complete medium and treated with 15 µM NA, 100 ng/ml TNF-alpha or a combination of NA and TNF-alpha for 24 h. After staining cells with trypan blue solution (0.4%), cell survival was quantified by measuring dye exclusion. Cell viability was determined as a percentage of control cells. For the apoptosis assay, HeLa cells were transfected with plasmids encoding p65, p65D97A, or Delta p65 with pEGFP-C1 plasmid (CLONTECH) that encodes green fluorescence protein. Apoptotic cells were identified by their rounded morphology, compared with the stead-out morphology of non-apoptotic cells. The number of apoptotic cells were counted and presented as a percentage of the total population of fluorescent cells.

DNA Fragmentation-- Cells were lysed in 400 µl of lysis buffer (10 mM Tris-HCl (pH 8.0), 100 mM NaCl, 25 mM EDTA (pH 8.0), 0.5% sodium dodecyl sulfate (SDS), 0.1 mg/ml proteinase K), and incubated at 50 °C for 15 h. DNA was prepared using phenol/chloroform extraction and precipitated with ethanol. After treatment with RNase A (0.1 mg/ml) for 2 h, DNA samples were separated by electrophoresis on 1.5% agarose gels, and visualized with ethidium bromide staining.

Preparation of Nuclear Extracts-- Cells were washed twice with ice-cold phosphate-buffered saline, harvested by centrifugation, and lysed in 400 µl of buffer A (10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride) for 15 min. Samples were made up to a volume of 25 µl with 10% (v/v) Nonidet P-40 and vortexed for 10 s. After centrifugation at 2,700 × g for 30 s, individual supernatant fractions (cytosolic extracts) were transferred to new tubes. Pellets were treated with ice-cold Buffer C (20 mM HEPES (pH 7.9), 0.4 mM NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride) and incubated for 15 min at 4 °C, followed by centrifugation at 20,000 × g for 5 min. Supernatants (nuclear extracts) were transferred to new tubes and kept frozen at -70 °C until further use.

Electrophoretic Mobility Shift Assay-- The NF-kappa B-specific oligonucleotide (5'-AACGGGACTTTCCGCTGGGGACTTTCCG-3') (Santa Cruz Biotechnology, Santa Cruz, CA) was end-labeled with [gamma -32P]ATP (Amersham Pharmacia Biotech) using T4 polynucleotide kinase (Roche Molecular Biochemicals). Electrophoretic mobility shift assays were performed by incubating 10 µg of nuclear extract with 2 µg of poly(dI-dC) (Amersham Pharmacia Biotech) in binding buffer (5 mM HEPES (pH 7.9), 5 mM MgCl2, 50 mM KCl, 0.5 M dithiothreitol, 10% glycerol) for 10 min at 37 °C. After incubation, end-labeled double-stranded oligonucleotide probe was added and the reaction mixture incubated for 10 min at 37 °C. Samples were separated by native polyacrylamide gel electrophoresis in low ionic strength buffer, following which dried gels were subjected to autoradiography.

Transient Transfection and Luciferase Assay-- HeLa cells were transiently transfected with NF-kappa B luciferase reporter plasmid for 12 h using the LipofectAMINE method according to manufacturer's instructions (Life Technologies). To assess the variation in transfection efficiencies, a control plasmid pCMV (CLONTECH) that expressed the LacZ gene was used. Following 48 h transfection, cells were treated with NA, TNF-alpha , or a combination of these compounds for 24 h. With a view to investigating the transcriptional activity of NF-kappa B, cells were transfected with p65, p65D97A, or Delta p65, together with NF-kappa B luciferase reporter plasmid. Luciferase assays were performed after 48 h transfection. Induction of luciferase expression was determined by Lumat LB9501 (Berthold), and standardized to the constitutive level of beta -galactosidase activity.

Western Blot Analysis-- Western blot analysis was carried out on 10 µg of nuclear extract. Following sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), proteins were electrophoretically transferred to polyvinylidene difluoride (Schleicher and Schuell). Membranes were blocked with TBS containing 0.5% Tween 20 in 5% skimmed milk, and subsequently incubated with the following primary antibodies: anti-p65 COOH terminus (SC-372, Santa Cruz), anti-p65 NH2 terminus (SC-109, Santa Cruz), anti-PARP (N-20, Serotech), anti-Fas (G254-274, Pharmingen), anti-FasL (C-178, Santa Cruz), anti-caspase-3 (C31720, Transduction Laboratory), anti-caspase-9 (SC-7885, Santa Cruz), and cytochrome c (65981A, Pharmingen). Membranes were washed with TBST and treated with secondary antibody conjugated with peroxidase. The quantity of protein present was detected using the enhanced chemiluminescence (ECL) detection system (Amersham Pharmacia Biotech), followed by exposure to film.

In Vitro Cleavage Assay-- In vitro transcription and translation were performed with the TNT-coupled reticulocyte system (Promega) and [35S]methionine (1,000 Ci/mmol, Amersham Pharmacia Biotech) according to the manufacturer's instructions. Aliquots of 3 µl of in vitro translated [35S]methionine-labeled p65 were incubated with 2 µl of recombinant caspases (caspase-3, caspase-1, or caspase-8) in the presence or absence of 10 µM YVAD-fmk or Ac-DEVD-CHO in reaction buffer (20 mM HEPES (pH 7.4), 100 mM NaCl, 0.5% Nonidet P-40, 10 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride) for 90 min at 30 °C. [35S]Methionine-labeled p65 and mutants (p65D97A or p65D469A) were incubated for 90 min with 200 µg of cell lysates prepared from cells treated with NA for 24 h at 30 °C. Samples were subsequently subjected to 10% SDS-PAGE and autoradiography.

Mutagenesis and Plasmid Construction-- Individual mutants of p65 were generated by site-directed mutagenesis. For the p65D97A mutant, p65 DNA (100 ng) was incubated with 100 pmol of mutagenic oligomers (5'-GAAAGGACTGCCGGGCTGGCTTCTATGAGGC-3' and 5'-GCCTCATAGAAGCCAGCCCGGCAGTCCTTTC-3'), and for the p65D469A construct, the oligomers (5'-ACCTGGCATCCGTCGCCAACTCCGAGTTTCA-3' and 5'-TGAAACTCGGAGTTGGCGACGGATGCCAGGT-3') were employed. The mutagenesis reaction was performed by polymerase chain reaction using cloned pfu polymerase (Stratagene), polymerase chain reaction was performed as follows: 50 s at 95 °C, 1 min at 55 °C, 15 min at 68 °C for 12 cycles. Base substitutions of these constructs were confirmed by automated DNA sequencing. Additionally, a NH2 terminus deletion mutant (Delta p65) was produced by polymerase chain reaction, using the following primers: 5'-GGGAAGCTTGGCTTCTATGAGGCTGAGC-3' and 5'-GGGGATCCTTAGGAGCTGATCTGACTCAGC-3.

Preparation of Cytosolic Fractions-- Cells were washed twice with ice-cold phosphate-buffered saline, resuspended in 5 volumes of Buffer A (50 mM Tris Cl (pH 7.5), 1 mM EDTA, 50 mM 2-mercaptoethanol, 0.2% bovine serum albumin, 10 mM KH2PO4, 0.4 M sucrose, 0.1 M phenylmethylsulfonyl fluoride, and 1 µg/ml pepstatin) and incubated on ice for 20 min. Following incubation, cells were treated with Nonidet P-40 (0.1%) and vortexed for 10 s. Unbroken cells and nuclei were pelleted by centrifugation at 6,000 × g for 5 min at 4 °C. Supernatant fractions were additionally centrifuged at 10,000 × g for 10 min at 4 °C to pellet mitochondria. After the second round of centrifuging, supernatants containing cytosol were transferred to new tubes.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

NA-induced Apoptosis in HeLa Cells-- NA has been shown to induce growth inhibition in human hepatocarcinoma cells (16). The effect of NA on growth in HeLa cells was investigated by treating cells with NA and examining cell viability. We observed a decrease in viability at 12 h, and entire loss of viability after 48 h, indicating that cell death occurs in a time-dependent manner (Fig. 1A). HeLa cells treated with TNF-alpha demonstrated continuous proliferation, thereby signifying resistance to cell death. However, cells treated with NA for 1 h prior to the addition of TNF-alpha once again showed significant cell death. In contrast, pretreatment with TNF-alpha notably reduced cell death induced by NA. In order to determine whether cells are killed via apoptotic processes, we examined internucleosomal DNA fragmentation (a well known biochemical characteristic) after treatment with NA. Apoptotic DNA laddering was faintly observed at 12 h (data not shown), and clearly present at 24 h following NA treatment. DNA fragmentation was not observed in cells exposed to TNF-alpha , but appeared during pretreatment with NA (Fig. 1B). These results imply that NA induces cell death in HeLa cells via an apoptotic pathway, and attenuates TNF-alpha -induced resistance against apoptosis.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of NA on the induction of apoptosis in HeLa cells. A, HeLa cells were treated with 15 µM NA or 100 ng/ml TNF-alpha for 24 h, TNF-alpha for 1 h before treatment with NA (TNF-alpha  + NA), or NA for 1 h prior to treatment with TNF-alpha (NA + TNF-alpha ). Cell survival was quantified at the indicated intervals by trypan blue dye exclusion. The percentage of cell survival was defined as the relative number of surviving untreated cells. B, apoptotic DNA fragmentation of the same samples was visualized by ethidium bromide staining, following 1.5% agarose gel electrophoresis.

TNF-alpha -induced NF-kappa B Activation Is Inhibited by NA Treatment-- The results illustrated in Fig. 1 suggest that NA might destroy survival signaling induced by TNF-alpha , and therefore induce cell apoptosis. NF-kappa B, a representative anti-apoptotic factor activated by TNF-alpha , protects cells from TNF-alpha -induced apoptosis (3). The key question that requires address is whether NA overrides TNF-alpha -induced resistance by blocking NF-kappa B activation. NF-kappa B activity was examined by electrophoretic mobility shift assay, using 32P-labeled NF-kappa B-specific oligonucleotide (see Fig. 2A for details). Treatment of HeLa cells with TNF-alpha resulted in remarkable activation of NF-kappa B, while NA failed to induce NF-kappa B activation. Moreover, TNF-alpha -induced activation of NF-kappa B was strongly repressed by pretreatment with NA. We next examined the transcriptional activity of NF-kappa B, using a luciferase assay. It was observed that TNF-alpha -induced luciferase expression is significantly inhibited upon pretreatment with NA (Fig. 2B), indicating that NA inhibits TNF-alpha -induced NF-kappa B activation and therefore obstructs NF-kappa B-stimulated anti-apoptotic signaling pathway. Our results suggest that inhibition of NF-kappa B activity may be part of the mechanism responsible for the apoptotic effect of NA.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 2.   NA reduces DNA binding activity and transcriptional activity of NF-kappa B induced by TNF-alpha . A, HeLa cells were treated simultaneously with NA and TNF-alpha for 30 min, or NA or TNF-alpha individually for 10 min before treatment with the other compound. Nuclear extracts were prepared and subjected to electrophoretic mobility shift assay with a radiolabeled double-stranded kappa B oligonucleotide. The arrow on the left-hand side of the panel indicates the NF-kappa B binding complex. B, HeLa cells were transfected with a NF-kappa B luciferase reporter plasmid (0.5 µg) for 48 h along with the same samples as in Fig. 1A. After treatment with the drugs for 12 h, luciferase activity was determined. The diagram is depicted as fold induction at the basal level. Each column represents an average (± S.E.) of three individual experiments.

NA Does Not Prevent Nuclear Translocation of p65-- It is known that NF-kappa B sequesters in the cytoplasm due to interactions with Ikappa B, and translocates to the nucleus in response to extracellular stimuli (2, 17). With a view to understanding the molecular mechanism of NA, we examined whether NA-mediated NF-kappa B suppression is achieved by perturbance of nuclear translocation of NF-kappa B. HeLa cells were exposed to NA or TNF-alpha for 30 min, and the level of p65, a subunit of NF-kappa B in nuclear fractions, was assessed. As shown in Fig. 3A, exposure of cells to TNF-alpha results in an increase in the level of p65 protein in cell nuclei, in contrast to nuclear p65 in NA-treated cells, where no increase is observed. However, the amount of TNF-alpha -induced nuclear p65 is not reduced by pretreatment with NA, indicating that NA does not interrupt nuclear translocation of p65 induced by TNF-alpha . From the above data, we conclude that inhibition of TNF-alpha -induced NF-kappa B activation by NA is not due to prevention of nuclear translocation of p65.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 3.   NA does not interrupt nuclear translocation of p65. A, HeLa cells were treated with either NA or TNF-alpha , or co-treated with these compounds for 30 min. Nuclear extracts (10 µg) of the cells were separated by 10% SDS-PAGE and Western blotting was performed with anti-p65 antibody. B, cells were treated with the compound as in Fig. 1A, and protein levels were monitored by Western blot analysis, using antibodies for p65 or PARP. Note that the asterisk on the right side of the Western blot of p65 indicates nonspecific bands.

p65 Is Cleaved during NA-induced Apoptosis-- The next step was to investigate whether there are any changes in the amount of nuclear p65 at 24 h when cells undergo apoptosis induced by NA treatment. It was found that the protein level of nuclear p65 in NA-treated cells is not altered, compared with that of control or TNF-alpha -treated cells (Fig. 3B). The cleavage of poly(ADP-ribose) polymerase (PARP), a predominant biochemical hallmark of apoptosis, was further observed in cells. Interestingly, the smaller band of p65 (Mr ~ 55,000) (Delta p65) was recognized in NA-treated cells, but not in the control or TNF-alpha -treated cells (Fig. 3B). The truncated p65 (Delta p65) is assumed to be a cleavage product generated during the apoptotic process. Experiments were conducted to analyze whether the appearance of Delta p65 is correlated with NA-induced apoptosis. As shown in Fig. 4A, the Delta p65 band firstly appears in cells treated with 10 µM NA for 24 h. In a time course experiment, this band was observed at 12 h after the addition of 15 µM NA (Fig. 4B). In contrast to the results obtained with p65, we could not observe any cleavage of p50, which is another component of NF-kappa B. Since PARP cleavage was observed at 24 h after treatment with NA (Fig. 4B, last panel), cleavage of p65 should be an earlier event. Our observations suggest that Delta p65 is the cleavage product of p65 produced during NA-induced apoptosis.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 4.   Cleavage of p65 correlates with NA-induced apoptosis. HeLa cells were treated with 0-20 µM NA for 24 h (A), or with 15 µM for an indicated time period (B). Nuclear extracts (10 µg) were fractionated by 10% SDS-PAGE, and subjected to immunoblotting with p65, p50, and PARP antibodies, respectively. The asterisk in the middle panel indicates a nonspecific band.

p65 Is Cleaved at Asp97 by Caspase-3-- It is known that various proteins are cleaved by caspase-3 during apoptosis (18-21). To evaluate whether caspases are responsible for p65 cleavage, cells were incubated with a caspase-3-specific inhibitor (Ac-DEVD-CHO), and an inhibitor for a broad spectrum of caspases (zVAD-fmk) for 1 h prior to treatment with NA. Cleavage of p65 was monitored by Western blot analysis. Upon treatment with Ac-DEVD-CHO, we failed to observe the appearance of both the cleavage product (Fig. 5A) and DNA fragmentation (Fig. 5B), which indicates that the cleavage of p65 is catalyzed by caspase-3. To provide direct evidence of this theory, in vitro-translated [35S]p65 was incubated with recombinant caspase-1, caspase-3, and caspase-8. It was noted that while p65 was cleaved by caspase-3 and inhibited by Ac-DEVD-CHO (Fig. 6), caspase-1 and caspase-8 had no effect on the cleavage of p65. In view of the data obtained, we conclude that p65 is a substrate of caspase-3 in vitro.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 5.   Caspase inhibitors block cleavage of p65 and DNA fragmentation. HeLa cells were incubated in the absence or presence of 10 µM Ac-DEVD-CHO or 10 µM zVAD-fmk for 1 h prior to treatment with 15 µM NA. Cells were harvested at 24 h after NA treatment, and divided into two samples for DNA fragmentation and Western blot analysis. A, equal amounts of nuclear cell extracts were separated by SDS-PAGE (10%) and subjected to Western blot analysis with anti-p65 antibody. B, DNA fragmentation was visualized by ethidium bromide staining, following agarose gel electrophoresis (1.5%).


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 6.   p65 is cleaved by caspase-3 in vitro. 35S-Labeled wild-type p65 was incubated with recombinant caspase-3 in the absence or presence of caspase inhibitors (Ac-DEVD-CHO or zVAD-fmk), caspase-1, or caspase-8 for 90 min at 30 °C. The reaction mixtures were subjected to 10% SDS-PAGE and the p65 fragment was visualized by autoradiography.

Caspase-3 has been shown to recognize and cleave specific substrates containing a conserved DXXD consensus tetrapeptide motif (22). Putative recognition sites for caspase-3 exist in the amino acid sequence of p65 (Asp-Cys-Arg-Asn97-Gly98, Asp-Thr-Asp-Asp294-Arg295, Ala-Ser-Val-Asp469-Asn470). In order to identify the cleavage site of p65 recognized by caspase-3, in vitro labeled [35S]p65 was incubated with caspase-3, and Western blot analysis was performed using antibodies against the COOH and NH2 termini of p65. The Delta p65 band was recognized by an antibody against the COOH terminus, but not by anti-NH2 terminus antibody (Fig. 7A). Moreover, the Delta p65 mutant generated during NA-induced apoptosis was not recognized by the NH2 terminus-specific antibody (Fig. 7B). Taken together, the results clearly demonstrate that p65 is cleaved by caspase-3 at the NH2 terminus. To determine the exact cleavage site, we introduced point mutations at Asp97 (p65D97A) and Asp469 (p65D469A). Wild-type (wt) p65 and the two p65 mutants were translated in vitro and incubated with cell lysates prepared from NA-treated cells. As shown in Fig. 7C, p65D97A was resistant to caspase-3 in cell lysates, while wt p65 and p65D469A mutant proteins were cleaved. Our results confirm that caspase-3 cleaves the Asp-Cys-Arg-Asp97-Gly98 motif of p65 during NA-induced apoptosis. The findings so far implicate that NF-kappa B might be inactivated through caspase-3-mediated cleavage of p65 after the Asp97 residue during NA-induced apoptosis.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 7.   Caspase 3-mediated cleavage of p65 occurs at the NH2 terminus. A, in vitro translated 35S-labeled p65 was incubated with recombinant caspase-3 alone, or in the presence of 10 µM caspase inhibitors, Ac-DEVD-CHO or zVAD-fmk. The reaction mixture was separated by 10% SDS-PAGE and subjected to Western blot analysis with specific antibodies against the COOH and NH2 termini of p65, respectively. B, HeLa cells were treated with NA for the indicated time period. Cell lysates were subjected to SDS-PAGE (10%), followed by Western blot analysis using polyclonal antibody against the NH2 terminus of p65. C, HeLa cells were treated with 15 µM NA for 24 h and cell lysates were prepared. Aliquots of 5 µl of in vitro translated [35S]Met-p65 and mutants ([35S]Met-p65D97A or [35S]Met-p65D469A) were incubated with 200 µg of cell lysate in the absence or presence of Ac-DEVD-CHO for 90 min at 30 °C. Reaction mixtures were further subjected to 10% SDS-PAGE, and autoradiography was performed on the dried gel.

Effect of Caspase-3-mediated Cleavage of p65 on Transcriptional Activity of NF-kappa B and NA-induced Apoptosis-- The role of caspase-3-mediated p65 cleavage on NF-kappa B activity and apoptosis was further investigated. The NH2 terminus of p65 contains a 300-amino acid Rel homology domain, which includes a DNA-binding domain, dimerization domain, and the nuclear translocation signal. In order to examine whether the transcriptional activity of NF-kappa B is disrupted by cleavage of p65, HeLa cells were co-transfected with NF-kappa B-luciferase reporter plasmid together with wild-type (wt) p65, caspase-3 resistant mutant (p65D97A), and caspase-3-cleaved COOH-terminal fragment of p65 (Delta p65), respectively, following which luciferase activity was monitored. NF-kappa B activity was reduced to half that of control in the Delta p65-transfected cells, while a 2-fold increase was observed in cells transfected with p65 or p65D97A (Fig. 8A). This suggests that cleavage of p65 at Asp97 impairs its DNA binding ability, and therefore leads to a reduction in the transcriptional activity of NF-kappa B.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of p65 cleavage on NF-kappa B activity and NA-induced apoptosis. A, HeLa cells were transfected with expression plasmids encoding p65, p65D97A, or Delta p65 (0.5 µg each), together with NF-kappa B-luciferase plasmid (0.5 µg). Cells were harvested 48 h after transfection, and a luciferase assay was performed. Experiments were performed in triplicate and averaged. B, cells were co-transfected with a pEGFP-C1 plasmid together with increasing concentration of p65, p65D97A, or Delta p65 (0.5, 1, and 2 µg of DNA). After treatment of cells with NA for 12 h, cells that underwent morphological changes were counted in GFP-expressing cells as a measure of apoptosis. The results depicted are representative of three separate experiments.

Experiments were subsequently conducted to analyze the effect of p65 cleavage on NA-induced apoptosis. Cells were expressed with different concentrations of p65, p65D97A, and Delta p65, together with GFP. NA-induced apoptosis was monitored by counting the number of dead GFP-positive cells after treatment with NA for 12 h (see Fig. 8B). Following exposure of cells to NA, apoptosis was significantly enhanced in Delta p65-transfected cells. In contrast, p65 and p65D97A inhibited apoptosis in a dose-dependent manner. However, p65D97A was more effective at apoptotic inhibition than wild-type p65, suggesting the requirement of intact p65 for the inhibition of apoptosis. We conclude from the data that NA induces caspase-3-mediated cleavage of p65, leading to the disruption of anti-apoptotic function of NF-kappa B, and consequently to cell death.

Caspase-3 Is Activated through Caspase-9 Signaling, Rather than the Caspase-8 Pathway during NA-induced Apoptosis-- The molecular mechanism linked to NA-induced activation of caspase-3 was further investigated in this study. Caspase-3 is activated by two main pathways. Ligation of Fas ligand (FasL) to Fas activates caspase-8, which in turn cleaves and activates other caspases including caspase-3 (23, 24). The second pathway involves the activation of caspase-3 by caspase-9. Caspase-9 is activated by cytochrome c released from mitochondria in the presence of Apaf-1 and dATP during apoptosis (25, 26). Previous reports demonstrated that ligation of Fas induces caspase-3-mediated cleavage of p65 at the COOH terminus during apoptosis in Jurkat T cells (13). This leads to the query as to whether caspase-3 is activated by an increase in Fas or FasL expression during NA-induced apoptosis (Fig. 9A). No change in the protein levels of Fas and FasL were observed following treatment with NA, indicating that Fas-stimulated caspase-8 signaling pathway is possibly not related to the activation of caspase-3 in our system.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 9.   Caspase-3 is activated through the cytochrome c-caspase-9 pathway during NA-induced apoptosis. A, HeLa cells were treated with NA for the indicated time periods. Expression levels of Fas and FasL were analyzed by Western blot analysis with either monoclonal or polyclonal antibody against FasL. B, HeLa cells were treated with TNF-alpha , NA, or a combination of these compounds for 24 h, and cytosolic extracts were prepared as described under "Experimental Procedures." Equal amounts of lysates were resolved by 10% SDS-PAGE (caspase-3 and caspase-9) or 14% SDS-PAGE (cytochome c), following which immunoblot analysis was performed using monoclonal antibody for caspase-3, and polyclonal antibodies for caspase-9 and cytochome c.

This leaves the possibility of the second pathway being preferentially in operation, that caspase-3 is activated through caspase-9. In order to examine this theory, HeLa cells were treated with TNF-alpha , NA, or a combination of these compounds. Cytosolic fractions of the cells were subjected to Western blot analysis for detection of cytochrome c and caspase-9 (Fig. 9B). Significant amounts of cytochrome c were released into the cytoplasm in NA-treated cells, but not in TNF-alpha -treated cells. Moreover, caspase-9 and caspase-3 were observed in concurrence with cytochrome c release. Taken together, these results indicate that NA activates caspase-3 and leads to p65 cleavage via cytochrome c/caspase-9 signaling, rather than the Fas/caspase-8 pathway.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The transcription factor, NF-kappa B, is activated by various stimuli, and protects against apoptosis (3, 27, 28). TNF-alpha can trigger two different pathways with opposite effects simultaneously, the apoptotic pathway mediated by caspase-8, and survival signaling mediated by NF-kappa B. It is known that TNF-alpha does not induce apoptosis unless NF-kappa B pathway is blocked (29). Previous studies have led to the discovery of the activation mechanism of NF-kappa B upon various apoptotic stimuli (1, 2, 4, 5). However, at present, it is currently unclear how apoptotic pathways overcome survival signaling mediated by NF-kappa B, and consequently induce cell death. In this article, we investigate whether the anti-apoptotic signaling mediated by NF-kappa B is inhibited during apoptosis induced by NA. We show that NA triggers apoptotic cell death in HeLa cells and destroys resistance to apoptosis caused by TNF-alpha . Furthermore, NA inhibits NF-kappa B activation through caspase-3-mediated cleavage of p65 at the NH2 terminus during apoptosis in HeLa cells.

There is ample evidence in earlier literature to illustrate that the activity of NF-kappa B is inhibited by various drugs via a number of mechanisms. Glucocorticoids inhibit NF-kappa B activity by increasing levels of Ikappa Balpha , and consequently sequestering NF-kappa B in the cytoplasm (9). Moreover, NF-kappa B activation is prevented by anti-inflammatory drugs like sodium salicylate and aspirin (10), which prevent degradation of Ikappa B by inhibiting the activity of Ikappa B kinase beta  (IKKbeta ). Proteosome inhibitors additionally block degradation of Ikappa B (11). It was reported that 3-deazaadenosine, which is known to induce apoptosis in human and mouse leukemia cells, inhibits the transcriptional activity of NF-kappa B through obstruction of p65 phosphorylation without reducing DNA binding activity (12). Our present analyses demonstrate that activation of NF-kappa B is inhibited by proteolytic cleavage of p65 during NA-induced apoptosis. The cleavage, induced by caspase-3, occurs at a site in the NH2 terminus of the protein. Another recent study showed that ligation of Fas repressed NF-kappa B activity in Jurkat T cells by inducing proteolytic cleavage of p65 and p50 during apoptosis (13). Data presented in this study indicate that p65 cleavage occurs at the COOH terminus, although also mediated by caspase-3. The cleavage at the COOH terminus of p65 was further examined during apoptosis induced by deprivation of growth factor (14), where caspase-6 and -7 are available for the COOH-terminal cleavage of p65, as well as caspase-3. Note that our results on the cleavage site of p65 at the NH2 terminus are significantly different from previous reports, although the fact that caspase-3 is responsible for the cleavage is universally established. With a view to explaining the dissimilar findings, we cannot exclude the possibility that another caspase is involved in the cleavage at this site, because the cell lysate had a higher activity of caspase than recombinant caspase-3 on the cleavage of p65 (Fig. 7C). The identity of these caspases is still somewhat ambiguous. It is difficult to explain why activated caspase-3 targets only the NH2 terminus of p65 during NA-induced apoptosis. One possible explanation for this discrepancy is that the activation mechanism of caspase-3 or the environment in which caspase-3 targets p65 in our system might be different from that in the other studies conducted so far.

It has been demonstrated that caspase-3 activation is regulated by at least two mechanisms. One involves a direct pathway from caspase-8 (23, 24), and the other is mediated by caspase-9, following the release of cytochrome c from mitochondria (25, 26). NA induces apoptosis via cytochrome c release into the cytoplasm and activation of caspase-9 (Fig. 9). However, the expression profiles of Fas and FasL do not change during NA-induced apoptosis, suggesting that caspase-3 is activated by caspase-9 rather than caspase-8. It must therefore be concluded that two caspase-3 activation pathways exist differently that both ultimately lead to the cleavage of p65. One might mediate the NH2-terminal cleavage of p65 in NA-induced apoptosis, while the other mediates the COOH-terminal cleavage of p65 in Fas-induced apoptosis.

During analyses on NF-kappa B transcriptional activity using the p65 mutants, it was noted that the p65 mutant truncated at the NH2 terminus (Delta p65) inhibits NF-kappa B-dependent transcription by half that of the control protein following overexpression (Fig. 8A). These data can be explained by the functional structure of p65. The NH2 terminus of p65 contains a Rel homology domain within which lies a DNA-binding domain, dimerization domain, and nuclear localization signal. Proteolytic cleavage at this site might impair the DNA binding ability of p65, therefore leading to a decrease in the transcriptional activity of NF-kappa B.

Overexpression of the deletion mutant Delta p65 significantly increases NA-induced apoptosis, while uncleavable p65 mutant (p65D97A) blocks apoptosis (Fig. 8B). Several genes induced by NF-kappa B are known to down-regulate apoptosis, including manganese superoxide dismutase (30), zinc finger protein A20 (31), and cellular inhibitor for apoptosis (CIAP) (32). Thus, the abrogation of transcriptional activity of NF-kappa B by caspase-3-mediated cleavage of p65 might diminish the anti-apoptotic effect of NF-kappa B during apoptosis, which in turn explains why cells are more sensitive to apoptosis by NA.

In conclusion, we suggest that NA represses NF-kappa B activity via caspase-3-mediated cleavage of p65, therefore sensitizing cells to apoptosis. Although the apoptotic mechanism of NA is currently unclear, down-regulation of NF-kappa B activity is evidently one of the active processes in NA-induced apoptosis. Several anticancer agents are less effective in the induction of apoptosis because of their concomitant activation of NF-kappa B. In this regard, NA might be a promising future candidate for cancer therapy.

    ACKNOWLEDGEMENTS

We thank Dr. Y. K. Jung for generously providing recombinant caspase-1, -3, and -8, and numerous helpful discussions, Dr. I. S. Kim for the human p65 and p50 cDNA, and Dr. J. W. Kim for the NF-kappa B-luciferase reporter plasmid.

    FOOTNOTES

* This work was supported in part by Korean Science Foundation Grant 1999-1-207-004-3 and Korean Ministry of Health and Welfare Grant HMP-98-D-4-0035.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Biology, College of Natural Sciences, Chung-Ang University, Heukseuk Dong, Dongjak Ku, Seoul 156-756 Korea. Tel.: 82-2-820-5209; Fax: 82-2-824-7302; E-mail: khchoi@cau.ac.kr.

Published, JBC Papers in Press, April 24, 2001, DOI 10.1074/jbc.M101291200

    ABBREVIATIONS

The abbreviations used are: NF-kappa B, nuclear factor kappa B; TNF-alpha , tumor necrosis factor alpha ; NA, naphthoquinone analog; GFP, green fluorescence protein; PAGE, polyacrylamide gel electrophoresis; PARP, poly(ADP-ribose) polymerase; Ac-DEVD-CHO, Ac-Asp-Glu-Val-Asp-CHO; z-VAD-fmk, z-Val-Ala-Asp-CH2F.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Baeuerle, P. A., and Baltimore, D. (1996) Cell 87, 13-20[Medline] [Order article via Infotrieve]
2. May, M. J., and Ghosh, S. (1997) Semin. Cancer Biol. 8, 63-73[CrossRef][Medline] [Order article via Infotrieve]
3. Beg, A. A., and Baltimore, D. (1996) Science 274, 782-784[Abstract/Free Full Text]
4. Brockman, J. A., Scherer, D. C., McKinsey, T. A., Hall, S. M., Qi, X., Lee, W. Y., and Ballard, D. W. (1995) Mol. Cell. Biol. 15, 2809-2818[Abstract]
5. Brown, K., Gerstberger, S., Carlson, L., Franzoso, G., and Siebenlist, U. (1995) Science 267, 1485-1488[Medline] [Order article via Infotrieve]
6. Chen, Z., Hagler, J., Palombella, V. J., Melandri, F., Scherer, D., Ballard, D., and Maniatis, T. (1995) Genes Dev. 9, 1586-1597[Abstract]
7. Traenckner, E. B., Pahl, H. L., Henkel, T., Schmidt, K. N., Wilk, S., and Baeuerle, P. A. (1995) EMBO J. 14, 2876-2883[Abstract]
8. Whiteside, S. T., Ernst, M. K., LeBail, O., Laurent-Winter, C., Rice, N., and Israel, A. (1995) Mol. Cell. Biol. 15, 5339-5345[Abstract]
9. Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., and Karin, M. (1995) Science 270, 286-290[Abstract]
10. Kopp, E., and Ghosh, S. (1994) Science 265, 956-959[Medline] [Order article via Infotrieve]
11. Griscavage, J. M., Wilk, S., and Ignarro, L. J. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 3308-3312[Abstract/Free Full Text]
12. Jeong, S. Y., Ahn, S. G., Lee, J. H., Kim, H. S., Kim, J. W., Rhim, H., Jeong, S. W., and Kim, I. K. (1999) J. Biol. Chem. 274, 18981-18988[Abstract/Free Full Text]
13. Ravi, R., Bedi, A., and Fuchs, E. J. (1998) Cancer Res. 58, 882-886[Abstract]
14. Levkau, B., Scatena, M., Giachelli, C. M., Ross, R., and Raines, E. W. (1999) Nat. Cell Biol. 1, 227-233[CrossRef][Medline] [Order article via Infotrieve]
15. Nishikawa, Y., Carr, B. L., wang, M., Kar, S., Finn, F., Dowd, P., Zheng, Z. B., Kerns, J., and Naganaathan, S. (1995) J. Biol. Chem. 270, 28304-28314[Abstract/Free Full Text]
16. Ham, S. W., Park, J. U., Lee, S. J., Kim, W. H., Kang, K. H., and Choi, K. H. (1998) Bioorg. Med. Chem. Lett. 8, 2507-2510[CrossRef][Medline] [Order article via Infotrieve]
17. Ghosh, S., May, M. J., and Kopp, E. B. (1998) Annu. Rev. Immunol. 16, 225-260[CrossRef][Medline] [Order article via Infotrieve]
18. Sakahira, H., Enari, M., and Nagata, S. (1998) Nature 391, 96-99[CrossRef][Medline] [Order article via Infotrieve]
19. Liu, X., Zou, H., Slaughter, C., and Wang, X. (1997) Cell 89, 175-184[Medline] [Order article via Infotrieve]
20. Ubeda, M., and Habener, J. F. (1997) J. Biol. Chem. 272, 19562-19568[Abstract/Free Full Text]
21. Rheaume, E., Cohen, L. Y., Uhlmann, F., Lazure, C., Alam, A., Hurwitz, J., Sekaly, R. P., and Denis, F. (1997) EMBO J. 16, 6346-6354[Abstract/Free Full Text]
22. Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., Munday, N. A., Raju, S. M., Smulson, M. E., Yamin, T. T., Yu, V. L., and Miller, D. K. (1995) Nature 376, 37-43[CrossRef][Medline] [Order article via Infotrieve]
23. Nunez, G., Benedict, M. A., Hu, Y., and Inohara, N. (1998) Oncogene 17, 3237-3245[CrossRef][Medline] [Order article via Infotrieve]
24. Enari, M., Talanian, R. V., Wong, W. W., and Nagata, S. (1996) Nature 380, 723-726[CrossRef][Medline] [Order article via Infotrieve]
25. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. (1997) Cell 91, 479-489[Medline] [Order article via Infotrieve]
26. Green, D. R., and Reed, J. C. (1998) Science 281, 1309-1312[Abstract/Free Full Text]
27. Wang, C. Y., Mayo, M. W., and Baldwin, A. S., Jr. (1996) Science 274, 784-787[Abstract/Free Full Text]
28. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. (1996) Science 274, 787-789[Abstract/Free Full Text]
29. Ashkenazi, A., and Dixit, V. M. (1998) Science 281, 1305-1308[Abstract/Free Full Text]
30. Perera, C. S., St. Clair, D. K., and McClain, C. J. (1995) Arch. Biochem. Biophys. 323, 471-476[CrossRef][Medline] [Order article via Infotrieve]
31. Opipari, A. W., Jr., Hu, H. M., Yabkowitz, R., and Dixit, V. M. (1992) J. Biol. Chem. 267, 12424-12427[Abstract/Free Full Text]
32. Chu, Z. L., McKinsey, T. A., Liu, L., Gentry, J. J., Malim, M. H., and Ballard, D. W. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 10057-10062[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.